（一）代表性论文

1．Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, Zhang Y,Zheng J. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma.Pharmacol Res. 2023 Mar;189:106701.

2．Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z,Zheng J*, Xu K*. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.J Clin Oncol. 2022 Jul 10;40(20):2246-2256.

3．Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A,Zheng J*, Xu K*. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.Blood. 2022 Jun 9;139(23):3376-3386.

4．Di J, Jiang N, Zheng Y, Wang J, Fang L, Li H, Yang J, Hu A, Xiao P, Zhang Q, Chai D*,Zheng J*,Wang G*. Adenovirus vaccine therapy with CD137L promotes CD8 DCs-mediated multifunctional CD8 T cell immunity and elicits potent anti-tumor activity.Pharmacol Res. 2022 Jan;175:106034.

5．Wu B, Zhang G, Guo Z, Wang G, Xu X, Li JL, Whitmire JK,Zheng J*, Wan YY*. The SKI proto-oncogene restrains the resident CD103+CD8+T cell response in viral clearance.Cell Mol Immunol. 2021 Oct;18(10):2410-2421.

6．Lu M, Zhang X, Gao X, Sun S, Wei X, Hu X, Huang C, Xu H, Wang B, Zhang W, Li Z, Feng X,Zheng J*, Zhang Q*. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.Pharmacol Res. 2021 Dec;174:105829.

7．Li Z, Wang D, Lu J, Huang B, Wang Y, Dong M, Fan D, Li H, Gao Y, Hou P, Li M, Liu H, Pan ZQ,Zheng J*, Bai J*. Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 2020 Dec;27(12):3226-3242.

8．Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L, Jing G, Sang W, Zhu F, Chen W, Wu Q, Yao Y, Wang G, Zhao J,Zheng J*, Li Z, Xu K. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.Lancet Haematol. 2019 Oct;6(10):e521-e529.

9．Wu B, Zhang S, Guo Z, Wang G, Zhang G, Xie L, Lou J, Chen X, Wu D, Bergmeier W,Zheng J*, Wan YY*. RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs.Immunity. 2018 Nov 20;49(5):886-898.e5. doi: 10.1016/j.immuni.2018.09.004.

10．Cao J,Wang G, Cheng H, Chen W, Qi K, Sang W, Li Z, Shi M, Li H, Qiao J, Pan B, Zhao J, Wu Q, Zeng L, Niu M, Jing G,Zheng J*, Xu K*. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/ refractory acute lymphoblastic leukemia.Am J Hematol. 2018, 93(7):851-858.

（二）科技奖励

1．2022年，淋巴细胞发育分化及抗肿瘤研究，中华医学科技奖二等奖

2．2019年，肿瘤分子靶点筛选及其抗肿瘤作用研究，江苏省科学技术奖一等奖

3．2015年，IL-18、IL-24抗肿瘤作用及其机制，教育部自然科学奖二等奖

4．2015年，IL-24基因工程产品制备及其抗肿瘤作用研究，江苏省科学技术奖三等奖

5．2012年，以重组腺病毒为载体的基因疗法对恶性肿瘤治疗的临床前期研究，教育部自然科学奖二等奖

6．2010年，Ki67基因为靶点的多种基因阻断技术治疗肾癌研究，中华医学科技奖三等奖

7．2010年，IL-18基因工程产品制备及其抗肿瘤作用研究 ，江苏省科学技术奖三等奖

8．2009年，RNA干扰抑制肾癌生长的体内外研究，江苏省科技进步奖三等奖

9．2006年，放射性核素反义治疗肾癌的临床前期研究，江苏省科技进步奖三等奖

10．2003年，肾癌Fas、FasL表达异常与免疫逃避及临床治疗失败机制研究，江苏省科技进步奖三等奖